Revenue Comparison
Chart: Revenue Comparison. Values in USD_BILLIONS. In Q2 2026: BioNTech 0.114, CSL 3.6525.
* CSL reports semi-annually. Values are evenly split across both quarters within each half.
BioNTech vs CSL: Revenue Comparison
BioNTech (BNTX) and CSL (CSL.AX) are peers in Vaccines. BioNTech reported revenue of $114M as of Q2 2026, compared with $7.3B for CSL. CSL leads on revenue.
BioNTech's gross margin is 8.1% versus 44.4% for CSL. BioNTech's net margin is -777.3% versus -40.2% for CSL.
Latest Quarter Comparison
Table: Latest Quarter Comparison. 15 rows across Metric, BioNTech, CSL.| Metric | BioNTech | CSL |
|---|---|---|
| Market Cap | - | - |
| Revenue | $114.00M | $7.30B |
| Cost of Revenue | $105.00M | $4.06B |
| Gross Profit | $9.00M | $3.24B |
| Operating Income | $-1.02B | $1.39B |
| Net Income | $-886.00M | $-2.94B |
| R&D Expense | $595.00M | $614.00M |
| Earnings Per Share | -$3.5 | -$6.14 |
| Gross Margin | 8.1% | 44.4% |
| Operating Margin | -897.8% | 19.0% |
| Net Profit Margin | -777.3% | -40.2% |
| Free Cash Flow | $-48.00M | $1.76B |
| Cumulative Free Cash Flow | $19.56B | $21.56B |
| Operating Cash Flow | $12.00M | $2.09B |
| Cash & Equivalents | $10.52B | $1.51B |